Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose study (NCT03626415) investigated the effect of hepatic impairment on pharmacokinetics (PK), safety, and tolerability of ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ellen Q., Le, Vu, O'Gorman, Melissa, Tripathy, Sakambari, Dowty, Martin E., Wang, Lisy, Malhotra, Bimal K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518898/
https://www.ncbi.nlm.nih.gov/pubmed/33749838
http://dx.doi.org/10.1002/jcph.1858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518898/
https://www.ncbi.nlm.nih.gov/pubmed/33749838
http://dx.doi.org/10.1002/jcph.1858

Ejemplares similares